PINEHURST – FirstHealth of the Carolinas made history last week when Moore Regional Hospital was the first place to enroll a patient in a clinical trial that employs a combined remedy regimen for COVID-19 consisting of an antiviral re-disdivir and a highly concentrated solution of SARS-CoV-2 antibodies, the disease to blame for COVID-19.
Gretchen Arnoczy, M. D. , an infectious disease doctor at FirstHealth, is the trial researcher at FirstHealth.
It is performed in adults hospitalized with COVID-19 in the United States, Mexico and 16 other countries on five continents The National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, sponsors and reverses Phase 3, called Hospital Treatment with Anti-Coronavirus Immunoglobulin, or ITAC.
The antibody solution tested in the ITAC assay is intravenous immunoglobulin anti-coronavirus hyperimmune, or hIVIG Antibodies in HIVIG anti-coronavirus come from the liquid component of blood or plasma, administered through other healthy people who have recovered from COVID-19 These antibodies are highly purified and concentrated, so hIVIG anti-coronavirus systematically has several times more neutralizing antibodies than those commonly found in other people’s plasma that have been recovered from COVID-19.
‘It’s different from convalescence plasma in that the amount of antibodies is normalized and the antibodies that are infused are known to neutralize the virus,’ Dr. Arnoczy said. ‘It was expected that by giving other people with COVID-19 those’ ready-to-use ‘antibodies at the onset of COVID-19 symptoms, before the framework reacts alone, it may be just the herbal immune reaction of the FRAMEWORK to COVID. -19 and patients can recover more temporarily and decrease the threat of serious illness and death. »
Study participants will be randomly assigned to obtain HIVIG and remdesivir or placebo anti-coronavirus infusions and re-use them. Neither the participants nor the examination team will know who is receiving what remedy regimen.
Remdesivir is a broad-spectrum antiviral in research discovered and developed through Gilead Sciences, Inc. Foster City, California.
FirstHealth has been using remdesivir to treat hospitalized COVID-19 patients since May, and the hospital also continues to treat patients with convalescent plasma.
“We are incredibly pleased that this partnership with the National Institutes of Health is a site for the ITAC trial,” said Dr. Arnoczy. “There is an urgent desire to find and effective remedies for COVID-19, and we feel privileged to take part in research activities aimed at offering remedies and answers to this crisis.
For more data on the ITAC test, ClinicalTrials. gov, NCT04546581
‘Really an angel’: a DAISY award-winning hospice nurse
Next article